#ICYMI: Episode 2 of The UroGist is now available on Apple Podcasts and Spotify! Join Michael Louie, MD MPH MSc, and Jennifer Linehan, MD, as they explore how antegrade administration is used for treating patients with low-grade upper tract urothelial cancer (LG-UTUC). Don’t miss this insightful discussion!?? ?? Whether you’re a urologist or healthcare professional looking to deepen your understanding of LG-UTUC, this conversation offers valuable insights and discussion on real-world case studies you won’t want to miss.? Listen now on Spotify: https://bit.ly/3Yl8y7F or Apple Podcasts: https://bit.ly/3Uei6QX
关于我们
UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel? drug delivery technology, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery technology has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase 3, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We are continually evaluating new partnership opportunities.
- 网站
-
https://urogen.com/
UroGen Pharma的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Princeton，New Jersey
- 类型
- 上市公司
- 创立
- 2004
地点
UroGen Pharma员工
动态
-
#ICYMI – last week The UroGist launched! In the first episode, Michael Louie, MD MPH MSc and Dr. Katie Murray discuss our insights into treatment approaches for low-grade upper tract urothelial cancer patients, including, diagnosis and treatment challenges, and more.? Listen now on Spotify: https://bit.ly/3Yl8y7F or Apple Podcasts: https://bit.ly/3Uei6QX
-
-
We’re excited to connect with urologists and leading industry experts in #urology at the LUGPA Annual Meeting this week. We’ll be at booth 504 and look forward to the discussions on improving communication and supporting better clinical outcomes for patients. #LUGPA2024
-
-
Our new podcast, The UroGist, is streaming on Spotify and Apple Podcasts. If you want to be a part of an engaging virtual community that exchanges ideas and insights and tackles complexities surrounding urologic oncology, you’ve come to the right place. Check out our series on Spotify: https://bit.ly/3Yl8y7F or Apple Podcasts: https://bit.ly/3Uei6QX
-
-
Tomorrow, members of our management team will participate in a fireside chat during the?Guggenheim Partners?Securities Healthcare Conference. Register for the webcast: https://bit.ly/3UGBFRR
-
-
We’re sharing our 2024 Q3 financial results in a live, recorded webcast today at 10am ET. Tune in to hear the updates: https://bit.ly/4feDk9M
-
-
See UroGen’s 2024 Q3 financial results during a live webcast on November 6 at 10:00 AM ET. Click below to tune in: https://bit.ly/3BY3H4T
-
-
The?Bladder Cancer Advocacy Network?(BCAN) brings together #bladdercancer patients, survivors, and caregivers to share their unique experiences. We’re proud to sponsor the 2024 Fall BCAN Summit for Patients and Families, an important event supporting the bladder cancer community. Learn more:?https://bcan.org/
-
-
In this episode of The UroGist, join Michael Louie, MD MPH MSc, and Jennifer Linehan, MD, as they dive into how antegrade administration is used for a low-grade upper tract urothelial cancer treatment. Listen now on Spotify: https://bit.ly/3Yl8y7F or Apple Podcasts: https://bit.ly/3Uei6QX
-
The Journal of Urology published 12-month duration of response data from the ENVISION study, which examines our investigational treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). See the results: https://bit.ly/4hfOzQy
-